合計 50 件の最近のインサイダー取引記録が記録されています Soleno Therapeutics, Inc. (SLNO), 内訳は 23 件の買い および 22 件の売り. インサイダー買い総額は $21.22M インサイダー売り総額は $129.87M.
最近活動のある主要インサイダーには Manning Meredith, Huang Michael F., Fulk Jennifer. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — SLNO
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-27 |
Manning Meredith |
Chief Commercial Officer |
情報に基づく売り |
558 |
$31.72 |
$17.7K |
64,507 |
| 2026-03-27 |
Huang Michael F. |
Sr. VP of Clinical Development |
情報に基づく売り |
488 |
$31.72 |
$15.48K |
39,823 |
| 2026-03-02 |
Fulk Jennifer |
Officer |
不明 |
- |
- |
- |
- |
| 2026-03-02 |
Fulk Jennifer |
Chief Financial Officer |
RSU 付与（制限付株式） |
39,200 |
- |
- |
39,200 |
| 2026-01-21 |
Mackaness James H |
Chief Financial Officer |
RSU 付与（制限付株式） |
32,800 |
$43.65 |
$1.43M |
32,800 |
| 2026-01-21 |
Anish Bhatnagar |
Chief Executive Officer |
RSU 付与（制限付株式） |
131,400 |
$43.65 |
$5.74M |
131,400 |
| 2026-01-21 |
Yen Kristen |
See Remarks |
RSU 付与（制限付株式） |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2026-01-21 |
Manning Meredith |
Chief Commercial Officer |
RSU 付与（制限付株式） |
32,800 |
$43.65 |
$1.43M |
32,800 |
| 2026-01-21 |
Hirano Patricia C |
See Remarks |
RSU 付与（制限付株式） |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2026-01-21 |
Norrett Kevin |
Chief Business Officer |
RSU 付与（制限付株式） |
4,000 |
$43.65 |
$174.6K |
4,000 |
| 2026-01-21 |
Joshi Manher |
Chief Development Officer |
RSU 付与（制限付株式） |
4,700 |
$43.65 |
$205.16K |
4,700 |
| 2026-01-21 |
Huang Michael F. |
Sr. VP of Clinical Development |
RSU 付与（制限付株式） |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2025-12-15 |
Mackaness James H |
Chief Financial Officer |
RSU 源泉徴収 |
2,013 |
$49.95 |
$100.55K |
103,163 |
| 2025-12-15 |
Anish Bhatnagar |
Chief Executive Officer |
贈与（送付） |
100,000 |
- |
- |
469,456 |
| 2025-12-15 |
Yen Kristen |
See Remarks |
RSU 源泉徴収 |
904 |
$49.95 |
$45.15K |
27,239 |
| 2025-12-15 |
Manning Meredith |
Chief Commercial Officer |
RSU 源泉徴収 |
1,922 |
$49.95 |
$96K |
43,429 |
| 2025-12-15 |
Hirano Patricia C |
See Remarks |
RSU 源泉徴収 |
904 |
$49.95 |
$45.15K |
12,302 |
| 2025-12-15 |
Huang Michael F. |
Sr. VP of Clinical Development |
RSU 源泉徴収 |
812 |
$49.95 |
$40.56K |
36,005 |
| 2025-11-17 |
Norrett Kevin |
Officer |
不明 |
- |
- |
- |
- |
| 2025-11-17 |
Norrett Kevin |
Chief Business Officer |
RSU 付与（制限付株式） |
14,286 |
- |
- |
14,286 |
| 2025-11-10 |
Joshi Manher |
Officer |
不明 |
- |
- |
- |
- |
| 2025-11-10 |
Joshi Manher |
Chief Development Officer |
RSU 付与（制限付株式） |
16,071 |
- |
- |
16,071 |
| 2025-10-13 |
Hahn Mark W |
Officer |
不明 |
- |
- |
- |
- |
| 2025-10-13 |
Hahn Mark W |
Director |
RSU 付与（制限付株式） |
10,046 |
- |
- |
10,046 |
| 2025-07-01 |
Hirano Patricia C |
See Remarks |
情報に基づく売り |
3,830 |
$82.76 |
$316.97K |
13,206 |
| 2025-06-24 |
Hirano Patricia C |
See Remarks |
オプション行使（売却） |
266 |
$44.25 |
$11.77K |
- |
| 2025-06-05 |
Harris William G |
Director |
RSU 付与（制限付株式） |
3,991 |
- |
- |
19,392 |
| 2025-06-05 |
Pauls Matthew |
Director |
RSU 付与（制限付株式） |
3,991 |
- |
- |
10,491 |
| 2025-06-05 |
Bir Dawn Carter |
Director |
RSU 付与（制限付株式） |
3,991 |
- |
- |
16,991 |
| 2025-06-05 |
Volck Birgitte |
Director |
RSU 付与（制限付株式） |
3,991 |
- |
- |
17,536 |
| 2025-06-05 |
Sinclair Andrew |
Director |
RSU 付与（制限付株式） |
3,991 |
- |
- |
10,491 |
| 2025-04-01 |
Hirano Patricia C |
See Remarks |
情報に基づく売り |
3,782 |
$70.11 |
$265.16K |
27,036 |
| 2025-03-28 |
Vivo Opportunity, Llc |
10 Percent Owner |
情報に基づく売り |
333,557 |
$70.60 |
$23.55M |
4,458,294 |
| 2025-03-28 |
Pauls Matthew |
Director |
情報に基づく売り |
5,937 |
$71.55 |
$424.8K |
6,500 |
| 2025-03-28 |
Hirano Patricia C |
See Remarks |
オプション行使（売却） |
2,691 |
$33.60 |
$90.42K |
18,842 |
| 2025-03-27 |
Vivo Opportunity, Llc |
10 Percent Owner |
情報に基づく売り |
1,100,000 |
$67.80 |
$74.58M |
4,791,851 |
| 2025-03-27 |
Mackaness James H |
Chief Financial Officer |
オプション行使（売却） |
5,000 |
$2.60 |
$12.98K |
- |
| 2025-03-27 |
Anish Bhatnagar |
Chief Executive Officer |
オプション行使（売却） |
16,666 |
$25.05 |
$417.48K |
- |
| 2025-03-27 |
Yen Kristen |
See Remarks |
オプション行使（売却） |
4,888 |
$5.10 |
$24.93K |
2,445 |
| 2025-03-27 |
Manning Meredith |
Chief Commercial Officer |
情報に基づく売り |
37,000 |
$67.04 |
$2.48M |
45,351 |
| 2025-03-27 |
Hirano Patricia C |
See Remarks |
オプション行使（売却） |
6,000 |
$24.00 |
$144K |
- |
| 2025-03-27 |
Huang Michael F. |
Sr. VP of Clinical Development |
情報に基づく売り |
10,000 |
$70.03 |
$700.33K |
36,817 |
| 2025-03-26 |
Vivo Opportunity, Llc |
10 Percent Owner |
情報に基づく売り |
400,000 |
$65.80 |
$26.32M |
5,891,851 |
| 2025-01-21 |
Mackaness James H |
Chief Financial Officer |
RSU 付与（制限付株式） |
31,000 |
$49.17 |
$1.52M |
31,000 |
| 2025-01-21 |
Anish Bhatnagar |
Chief Executive Officer |
RSU 付与（制限付株式） |
115,600 |
$49.17 |
$5.68M |
115,600 |
| 2025-01-21 |
Yen Kristen |
See Remarks |
RSU 付与（制限付株式） |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-21 |
Manning Meredith |
Chief Commercial Officer |
RSU 付与（制限付株式） |
29,200 |
$49.17 |
$1.44M |
29,200 |
| 2025-01-21 |
Hirano Patricia C |
See Remarks |
RSU 付与（制限付株式） |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-21 |
Huang Michael F. |
Sr. VP of Clinical Development |
RSU 付与（制限付株式） |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-03 |
Mackaness James H |
Chief Financial Officer |
情報に基づく売り |
3,791 |
$46.18 |
$175.05K |
111,298 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
